Angiogenesis Inhibitor Development for Brain Tumors

Angiogenesis inhibitors for brain tumors are drugs that prevent the formation of new blood vessels, effectively starving the tumor of the necessary nutrients and oxygen needed for its growth. Alfa Cytology focuses on angiogenesis inhibitors for brain tumors, dedicated to developing innovative therapies that target the tumor's blood supply to inhibit its progression.

Mechanisms of Angiogenesis Inhibitors

Angiogenesis is the growth of new capillaries from pre-existing vessels and is a complex process involving the proliferation, migration, and differentiation of vascular endothelial cells (ECs) in response to specific signaling stimuli. Glioblastoma (GBM) in brain tumors is a highly vascularized tumor and glioma growth is dependent on the formation of new blood vessels.

Fig 1. Schematic representation of angiogenic events in glioblastoma. (AHIR B K, et al., 2020)

Our Services

Alfa Cytology focuses on anti-angiogenic therapies, and we provide targeted brain tumor drug development services targeting angiogenesis, particularly VEGF, to inhibit the proliferation of brain tumors, including GBM, by inhibiting the formation of new tumors blood vessels using angiogenesis inhibitors and drugs.

Targets	Description
Basic fibroblast growth factor (bFGF)	Present both in tumor cells and in the vascular basement membrane for sustained release and upregulation during angiogenesis.
Fibroblast growth factor receptor (FGFR)	FGFR regulates a range of angiogenic processes.
Hepatocyte growth factor/dispersion factor (HGF/SF)	HGF/SF is a heparin-binding mesenchymal-derived cytokine that regulates angiogenesis by both upregulating VEGF and inhibiting platelet response protein 1 (TSP-1).
Platelet-derived growth factor (PDGF)	PDGF proteins regulate angiogenesis by binding to and activating two cell surface receptor tyrosine kinase (RTK) receptors, PDGFR-α and PDGFR-β.
TGF-β	High levels of TGF-β are associated with poor prognosis in GBM and enhance the expression of several pro-angiogenic factors, such as VEGF, FGF, and PDGF-β.
Matrix metalloproteinases (MMP)	MMP selectively degrades components of the ECM and is associated with tumor cell invasion angiogenesis and inhibition of antitumor immune surveillance.
Angiopoietins (Angs)	Angs induce environment-dependent pro-angiogenic or anti-angiogenic effects.

Angiogenesis Inhibitors Development for Brain Tumor

Small Molecule Drug

Radionuclide Therapy

Therapeutic Antibody

Peptide Drug

Immune Cell Therapy

Gene Therapy

Workflow of Brain Tumor Angiogenesis Inhibitors Development

Target Identification and Validation

Select key angiogenesis-related targets (e.g., VEGF/VEGFR, FGF/FGFR, Angiopoietin-Tie2) pertinent to brain tumors and blood-brain barrier penetration. Validate these targets using gene knockout or RNA interference to confirm their role in inhibiting tumor angiogenesis, and analyze samples to ensure high target expression in brain tumor tissues.

Angiogenesis Inhibitors Design and Development

Design and develop inhibitors that specifically target the identified angiogenic factors, utilizing medicinal chemistry and computational modeling to create effective and selective compounds.

In Vitro Evaluation

Assess pharmacodynamics by testing compounds for inhibition of endothelial cell proliferation (e.g., MTT assays with HUVEC cells) and tube formation (e.g., Matrigel assays). Evaluate pharmacokinetics by examining solubility, metabolic stability, and blood-brain barrier permeability using models like Caco-2 cells and hCMEC/D3 cell monolayers.

In Vivo Evaluation

Develop animal models, such as xenografts with human brain tumor cells or transgenic models simulating primary brain tumor angiogenesis. Evaluate therapeutic efficacy through imaging (MRI, in vivo fluorescence) and histological analyses (microvessel density, necrosis). Assess pharmacokinetics and preliminary toxicity by measuring drug concentrations in plasma and brain tissue, and monitoring physiological parameters and biochemical markers.

Alfa Cytology offers comprehensive brain tumor drug development services with a specialized focus on angiogenesis inhibition. Please contact us to receive our latest proposals. We look forward to collaborating with you on the advancement of innovative, targeted therapies aimed at inhibiting angiogenesis in brain tumors.

Reference

AHIR B K, ENGELHARD H H, LAKKA S S. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma [J]. Molecular neurobiology, 2020, 57(5): 2461-78.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.